Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 2:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 3,913 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Prostate Cancer Clear all
Completed Phase 2 Interventional Results available

Radiation Therapy in Treating Patients With Prostate Cancer

NCT01434290
View directory record Official record
Conditions
Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment, Radiation Toxicity, Sexual Dysfunction
Interventions
36.25 Gy IMRT, 51.6 Gy IMRT
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
32
States / cities
Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2022 · Synced Oct 31, 2026, 2:26 AM EDT
Completed Not applicable Interventional

PROWESS (PROstate Cancer Wearables Exercise and Structured Supports): A Pilot Supportive Care Intervention

NCT05755490
View directory record Official record
Conditions
Prostate Cancer, Prostatic Neoplasms
Interventions
PROWESS
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 31, 2026, 2:26 AM EDT
Completed Not applicable Interventional Results available

Clinical Evaluation of the PROGENSA(Registered Trademark) Prostate Cancer Gene 3 (PCA3) Assay in Men With a Previous Negative Biopsy Result

NCT01024959
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
PCA3 Assay
Other
Lead sponsor
Gen-Probe, Incorporated
Industry
Eligibility
40 Years and older · Male only
Enrollment
507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
13
States / cities
Los Angeles, California • San Diego, California • Aventura, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2012 · Synced Oct 31, 2026, 2:26 AM EDT
Recruiting Phase 1 Interventional

Brodalumab in the Treatment of Immune-Related Adverse Events

NCT06673329
View directory record Official record
Conditions
Breast Cancer, Esophageal Cancer, Kidney Cancer, Lung Cancer, Thyroid Cancer, Gynecologic Cancer, Pancreatic Cancer, Stomach Cancer, Brain Tumor, Colon Cancer, Rectal Cancer, Head and Neck Cancer, Oral Cancer, Liver Cancer, Skin Cancer, Prostate Cancer, Testicular Cancer, Solid Tumor
Interventions
Brodalumab, CT scan
Drug · Radiation
Lead sponsor
Brian Henick, MD
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 31, 2026, 2:26 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

NCT04493853
View directory record Official record
Conditions
Hormone-Sensitive Prostate Cancer
Interventions
Capivasertib, Placebo, Abiraterone Acetate
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Male only
Enrollment
1,012 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
33
States / cities
Tucson, Arizona • La Jolla, California • Orange, California + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 31, 2026, 2:26 AM EDT
Recruiting Phase 1Phase 2 Interventional

Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate Cancer Patients

NCT06262139
View directory record Official record
Conditions
MRI Scan
Interventions
MT218 injection
Drug
Lead sponsor
Songqi Gao
Industry
Eligibility
18 Years to 90 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 31, 2026, 2:26 AM EDT
Completed Phase 1 Interventional

A Phase 1 Study of FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT03575819
View directory record Official record
Conditions
Prostate Cancer Metastatic
Interventions
FOR46
Drug
Lead sponsor
Fortis Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
5
States / cities
Los Angeles, California • San Francisco, California • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Oct 31, 2026, 2:26 AM EDT
Completed Phase 2 Interventional Results available

Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer.

NCT03315754
View directory record Official record
Conditions
Localized Prostate Cancer
Interventions
TOOKAD Soluble 4 mg/kg
Drug
Lead sponsor
Steba Biotech S.A.
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 31, 2026, 2:26 AM EDT
Completed Phase 1 Interventional

J591 in Patients With Advanced Prostate Cancer and Unfavorable Circulating Tumor Cell Counts

NCT02552394
View directory record Official record
Conditions
Prostate Cancer
Interventions
huJ591
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Oct 31, 2026, 2:26 AM EDT
Active, not recruiting Not applicable Interventional

UFPTI 2403-PR12: Real-Time Volumetric Ionizing Radiation Acoustic Imaging for In-vivo Proton Treatment Monitoring in Pencil-Beam Scanning

NCT06465966
View directory record Official record
Conditions
Prostate Cancer
Interventions
iRAI
Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 31, 2026, 2:26 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Prostate Cancer Education in African American Men

NCT01415375
View directory record Official record
Conditions
Prostate Cancer Screening Decision
Interventions
Prostate Cancer Screening Education, Fruit and Vegetable Intake Education
Behavioral
Lead sponsor
Temple University
Other
Eligibility
45 Years to 70 Years · Male only
Enrollment
490 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 17, 2015 · Synced Oct 31, 2026, 2:26 AM EDT
Completed Phase 2 Interventional Results available

Study With IMC-A12 (Cixutumumab) in Patients Who Have Not Previously Been Treated With Chemotherapy With Metastatic Prostate Cancer

NCT00520481
View directory record Official record
Conditions
Adenocarcinoma of the Prostate
Interventions
IMC-A12 (Cixutumumab)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
3
States / cities
San Francisco, California • Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced Oct 31, 2026, 2:26 AM EDT
Completed Phase 1 Interventional Results available

Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer

NCT01347788
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
cabozantinib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Oct 31, 2026, 2:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

DeADT - Living Well With Prostate Cancer

NCT06199986
View directory record Official record
Conditions
Prostate Cancer
Interventions
ADT Order Check Attestation (Or), Provider Script (Sc)
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Oct 31, 2026, 2:26 AM EDT
Completed Not applicable Interventional Results available

Optimizing Active Surveillance in Low-Risk Prostate Cancer: a Pilot Study

NCT05764005
View directory record Official record
Conditions
Prostate Cancer
Interventions
web-based tool (MAP- Management of Active surveillance in Prostate Cancer), MUSIC website
Behavioral
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
55 Years and older · Male only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 31, 2026, 2:26 AM EDT
Completed No phase listed Observational

A Study to Learn About Two Medicines (Apalutamide and Enzalutamide) in People With Metastatic Castration-sensitive Prostate Cancer (mCSPC)

NCT07086651
View directory record Official record
Conditions
Metastatic Castration Sensitive Prostate Cancer (mCSPC), Cancer of the Prostate, Prostate Neoplasms, Prostate Cancer
Interventions
Enzalutamide, Apalutamide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Oct 31, 2026, 2:26 AM EDT
Recruiting Phase 2 Interventional

A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide

NCT06844383
View directory record Official record
Conditions
Prostate Cancer (Adenocarcinoma), mCRPC (Metastatic Castration-resistant Prostate Cancer)
Interventions
Talazoparib with enzalutamide, Talazoparib
Drug
Lead sponsor
Prostate Cancer Clinical Trials Consortium
Other
Eligibility
18 Years and older · Male only
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
8
States / cities
Duarte, California • La Jolla, California • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 31, 2026, 2:26 AM EDT
Completed No phase listed Observational

SBRT for Oligometastatic Castration-Refractory Prostate Cancer

NCT02816983
View directory record Official record
Conditions
Prostate Cancer
Interventions
SBRT
Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 25, 2022 · Synced Oct 31, 2026, 2:26 AM EDT
Not yet recruiting Not applicable Interventional

Sexual Health Communication Skills Training Intervention for Patients With Prostate Cancer

NCT07655557
View directory record Official record
Conditions
Prostate Cancer
Interventions
Starting the Conversation (STC), Time and Attention
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 31, 2026, 2:26 AM EDT
Active, not recruiting Phase 1 Interventional

TH1902 in Patients With Advanced Solid Tumors

NCT04706962
View directory record Official record
Conditions
Solid Tumor, TNBC - Triple-Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer, Endometrial Cancer, Cutaneous Melanoma, Thyroid Cancer, Small-cell Lung Cancer, Prostate Cancer, SORT1+ Cancers
Interventions
TH1902
Drug
Lead sponsor
Theratechnologies
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
5
States / cities
Detroit, Michigan • Grand Rapids, Michigan • Gettysburg, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Oct 31, 2026, 2:26 AM EDT
Active, not recruiting No phase listed Observational

An Observational Registry Assessing the Impact of PYLARIFY® (Piflufolastat F18) PET in Patients With Prostate Cancer

NCT05712473
View directory record Official record
Conditions
Prostate Cancer
Interventions
PYLARIFY
Diagnostic Test
Lead sponsor
Lantheus Medical Imaging
Industry
Eligibility
21 Years and older · Male only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
12
States / cities
Homewood, Alabama • Little Rock, Arkansas • Fresno, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 31, 2026, 2:26 AM EDT
Active, not recruiting Phase 1 Interventional

Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC)

NCT01140373
View directory record Official record
Conditions
Prostate Cancer
Interventions
engineered autologous T cells, cyclophosphamide
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 31, 2026, 2:26 AM EDT
Completed Phase 1Phase 2 Interventional

Ixabepilone With or Without Estramustine in Treating Patients With Progressive Prostate Cancer

NCT00025194
View directory record Official record
Conditions
Prostate Cancer
Interventions
estramustine phosphate sodium, ixabepilone
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
4
States / cities
San Francisco, California • Boston, Massachusetts • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 31, 2026, 2:26 AM EDT
Not listed Early Phase 1 Interventional

Gadoxetate Sodium Enhanced MRI as a Biomarker for Aggressive Prostate Cancer

NCT03960788
View directory record Official record
Conditions
Cancer of the Prostate, Castration-resistant Prostate Cancer
Interventions
Gadoxetate Sodium
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 23, 2019 · Synced Oct 31, 2026, 2:26 AM EDT